Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
SOD of Interdisciplinary Internal Medicine, Azienda Ospedaliera Universitaria Careggi (AOUC), 50134 Florence, Italy.
Mediators Inflamm. 2021 Nov 11;2021:6926082. doi: 10.1155/2021/6926082. eCollection 2021.
The involvement of the human microbiome is crucial for different host functions such as protection, metabolism, reproduction, and especially immunity. However, both endogenous and exogenous factors can affect the balance of the microbiota, creating a state of dysbiosis, which can start various gastrointestinal or systemic diseases. The challenge of future medicine is to remodel the intestinal microbiota to bring it back to healthy equilibrium (eubiosis) and, thus, counteract its negative role in the diseases' onset. The shaping of the microbiota is currently practiced in different ways ranging from diet (or use of prebiotics, probiotics, and synbiotics) to phage therapy and antibiotics, including microbiota fecal transplantation. Furthermore, because microbiota modulation is a capillary process, and because many microbiota bacteria (both beneficial and pathogenic) have carbonic anhydrases (specifically the four classes , , , and ), we believe that the use of CA inhibitors and activators can open up new therapeutic strategies for many diseases associated with microbial dysbiosis, such as the various gastrointestinal disorders and the same colorectal cancer.
人类微生物组的参与对于宿主的不同功能至关重要,如保护、代谢、繁殖,特别是免疫。然而,内源性和外源性因素都可以影响微生物群的平衡,导致微生态失调,从而引发各种胃肠道或全身性疾病。未来医学的挑战是重塑肠道微生物群,使其恢复健康的平衡(稳态),从而抵消其在疾病发病中的负面作用。目前,通过不同的方法来塑造微生物群,包括饮食(或使用益生元、益生菌和合生菌)、噬菌体治疗和抗生素,包括粪便微生物群移植。此外,由于微生物群的调节是一个毛细血管过程,并且因为许多微生物群细菌(有益和致病的)都有碳酸酐酶(具体为四类 、 、 、 ),我们认为使用 CA 抑制剂和激活剂可以为许多与微生物失调相关的疾病(如各种胃肠道疾病和结直肠癌)开辟新的治疗策略。